<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204229">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430573</url>
  </required_header>
  <id_info>
    <org_study_id>R01 DA017904-S1</org_study_id>
    <secondary_id>R01DA017904</secondary_id>
    <nct_id>NCT00430573</nct_id>
  </id_info>
  <brief_title>Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use</brief_title>
  <official_title>Placebo-Controlled Evaluation of the Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines whether isolated doses of d-cycloserine enhance the efficacy of an
      exposure-based cognitive-behavioral treatment for chronic and treatment refractory substance
      dependence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a placebo-controlled trial of the efficacy of 50mg d-cycloserine or matching pill
      placebo for enhancing the efficacy of CBT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicology screens for illicit substances</measure>
    <time_frame>Weekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Addiction Severity Index, Risk Behavior Survey, Hamilton Anxiety Inventory, Montgomery-Asberg Depression Rating Scale, Anxiety Sensitivity Index</measure>
    <time_frame>Baseline, Mid Treatment, End of Treatment, 1-Month Follow-up, 2-Month Follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCS-augmented CBT-IC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo-augmented CBT-IC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-cycloserine</intervention_name>
    <description>Single dosage prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)</description>
    <arm_group_label>I</arm_group_label>
    <other_name>DCS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dosage prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)</description>
    <arm_group_label>II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        The primary selection criteria include women and men between the ages of 18 and 65 who:

          1. Meet DSM-IV criteria for opiate dependence,

          2. Maintain a stable dose of methadone for two weeks prior to recruitment and:

               -  fail to achieve &quot;take-home&quot; status for methadone dosing during at least the
                  first four months of methadone treatment,

               -  test positive on at least two toxicology screens for illicit drugs during the
                  month prior to recruitment

               -  have never achieved two consecutive toxicology screens free of illicit
                  substances since entering the current treatment episode.

          3. Meet study criteria for chronic stress:

               -  unemployment criteria, and

               -  affective disorder criteria.

        Exclusion Criteria:

          1. Patients with significantly unstable or uncontrolled medical illness which may
             interfere with participation in treatment (e.g., patients likely to require
             hospitalization during the study period).

          2. Patients with a psychotic or organic mental disorder according to DSM-IV criteria.

          3. Patients receiving medication affecting methadone metabolism (e.g. rifampin).

          4. Patients with uncontrolled bipolar disorder as evidenced by meeting current criteria
             for mania or hypomania or meeting criteria for rapid cycling in the last year (as
             indicated by structured questioning of all patients meeting criteria for bipolar
             disorder).

          5. Patients unable to complete the informed consent or unable to understand study
             procedures in the informed consent process.

          6. Pregnancy or current alcohol use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael W. Otto, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Habit OPCO</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>May 23, 2013</lastchanged_date>
  <firstreceived_date>January 31, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston University</investigator_affiliation>
    <investigator_full_name>Michael Otto</investigator_full_name>
    <investigator_title>Ph.D.</investigator_title>
  </responsible_party>
  <keyword>cognitive-behavior therapy</keyword>
  <keyword>d-cycloserine</keyword>
  <keyword>cognitive enhancer</keyword>
  <keyword>drug dependence</keyword>
  <keyword>opiate dependence</keyword>
  <keyword>exposure</keyword>
  <keyword>isolated doses of d-cycloserine</keyword>
  <keyword>isolated doses of matching pill placebo</keyword>
  <keyword>DCS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
